This has led to growing interest in inflammasome-targeted therapies, particularly NLRP3 inhibitors, which have emerged as promising alternatives for treating inflammation in gout beyond conventional NSAIDs and steroids [17]. The gene discussed is NLRP3; the disease is gout.